Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSONG.L Regulatory News (SONG)

  • There is currently no data for SONG

Kepler Trust Intelligence: New Research

24 Feb 2022 07:00

RNS Number : 6126C
Hipgnosis Songs Fund Limited
24 February 2022
 

Hipgnosis Songs: New Research

24/02/2022

SONG has continued to deliver, yet now trades at an attractive discount...

The investment companies team at Kepler Trust Intelligence has produced a new piece of investment bank quality research about the trust, designed to provide a clear and comprehensive reference for long term investors. This note is free to read for UK investors.

Click here to read the note in full.

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEASADADXAEFA
Date   Source Headline
19th Apr 202412:02 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
19th Apr 202411:38 amRNSForm 8.5 (EPT/NON-RI)-Hipgnosis Songs Fund Limited
19th Apr 202411:30 amRNSForm 8.5 (EPT/RI)-Hipgnosis Songs Fund Limited
19th Apr 202411:20 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
19th Apr 202410:38 amRNSForm 8.5 (EPT/RI)
19th Apr 202410:38 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20243:40 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20241:17 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202411:14 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202410:26 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20247:00 amRNSRECOMMENDED CASH OFFER FOR HIPGNOSIS
15th Apr 20247:00 amRNSChange to Director roles and responsibilities
28th Mar 20249:02 amRNSFinal Due Diligence Findings
18th Mar 20247:00 amRNSAmendment to Operative Net Asset Value
4th Mar 20249:27 amRNSUpdate on Due Diligence, Valuation and NAV
4th Mar 20247:00 amRNSUpdate on Due Diligence, Valuation and NAV
26th Feb 20247:00 amRNSLitigation update
19th Feb 20247:00 amRNSLitigation Update
7th Feb 202412:35 pmRNSResult of Extraordinary General Meeting (“EGM”)
5th Feb 20247:00 amRNSLitigation Update
23rd Jan 20247:00 amRNSPublication of Circular/Update to Strategic Review
18th Jan 20247:00 amRNSProposed Change to Articles of the Company
11th Jan 20247:00 amRNSDirectorate Change
4th Jan 20243:26 pmRNSHolding(s) in Company
21st Dec 20237:00 amRNSInterim results to 30 September 2023
20th Dec 20237:00 amRNSChange of Auditor
19th Dec 20237:00 amRNSDelay to publication of interim results
15th Dec 20237:00 amRNSDirectorate Change
11th Dec 20237:00 amRNSAsset sale, adviser appointment, notice of results
28th Nov 202312:52 pmRNSHolding(s) in Company
23rd Nov 20237:00 amRNSStrategic Review and Company Update
20th Nov 20237:00 amRNSDirector/PDMR Shareholding
7th Nov 20237:00 amRNSDirectorate Changes
6th Nov 20237:00 amRNSUpdate on dividend intentions
26th Oct 202311:20 amRNSResult of AGM and EGM
25th Oct 20234:00 pmRNSDirectorate Changes, withdrawal of AGM Resolutions
24th Oct 20237:00 amRNSConclusion of Go-Shop process
19th Oct 20237:00 amRNSInitiation of Strategic Review, update on RCF
17th Oct 202312:22 pmRNSHolding(s) in Company
17th Oct 202312:21 pmRNSHolding(s) in Company
17th Oct 202312:18 pmRNSHolding(s) in Company
16th Oct 20236:17 pmRNSUpdate on CRB III and dividend payment
16th Oct 20237:13 amRNSUpdate on CRB III impact and dividend payment
28th Sep 202311:07 amRNSPublication of Circular and Notice of AGM & EGM
25th Sep 20232:41 pmRNSHolding(s) in Company
22nd Sep 202310:49 amRNSHolding(s) in Company
21st Sep 20237:00 amRNSDividend Declaration
20th Sep 20237:00 amRNSHolding(s) in Company
14th Sep 20237:00 amRNSAsset sales to fund buy backs and reduce debt
14th Aug 202312:29 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.